Calochortus Tolmiei Whole

Dosage for Calochortus Tolmiei Whole is highly individualized and must be determined by an allergy specialist through a process of titration. There is no 'standard' dose that applies to all patients.

Diagnostic Dosing

• Percutaneous (Prick) Testing: Typically uses a 1:10 or 1:20 w/v concentration in a 50% glycerin base. A single drop is applied to the skin, and the skin is pricked through the drop.
• Intradermal Testing: If prick tests are negative, a more sensitive intradermal test may be performed using a much more dilute concentration, often ranging from 1:100 to 1:1,000 w/v, injecting 0.02 to 0.05 mL to create a small bleb.

Therapeutic Dosing (Immunotherapy)

• Build-up Phase: Treatment usually begins with a very dilute solution (e.g., 1:100,000 or 1:10,000 w/v). Injections are given once or twice weekly, with the dose increasing by 50% to 100% at each visit, provided no significant local or systemic reactions occur.
• Maintenance Phase: Once the 'top dose' or 'maintenance dose' is reached (often 0.5 mL of a 1:100 or 1:20 w/v concentration), the interval between injections is increased to every 2 to 4 weeks. This phase typically lasts 3 to 5 years.

Calochortus Tolmiei Whole is generally considered safe for use in children, though immunotherapy is rarely started in children under the age of 5 due to the difficulty of communication regarding systemic symptoms and the risk of anaphylaxis. Dosing for children follows the same titration principles as adult dosing, though the clinician may choose a more conservative build-up schedule.

Renal Impairment

No specific dosage adjustments are required for renal impairment, as the protein load is negligible. However, the patient's overall health and ability to tolerate a systemic reaction must be considered.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The risk of using epinephrine (the treatment for anaphylaxis) in patients with heart disease must be weighed against the benefits of immunotherapy.

Calochortus Tolmiei Whole must only be administered by a healthcare professional trained in the management of anaphylaxis.

• Preparation: The vial should be inspected for particulate matter or discoloration. Glycerinated extracts are viscous and require careful measurement.
• Administration Site: Subcutaneous injections for immunotherapy are typically given in the posterior aspect of the upper arm. The site should be rotated between visits.
• Observation: Patients must remain in the medical office for at least 30 minutes following any injection. Most fatal reactions to allergenic extracts occur within this window.
• Storage: Vials must be stored at 2°C to 8°C (36°F to 46°F). Freezing must be avoided as it can denature the proteins, rendering the extract ineffective or potentially dangerous.

In the context of immunotherapy, a missed dose requires a 'step-back' in the dosage to ensure safety.

• If a dose is missed for 1 week beyond the scheduled time, the previous dose may be repeated.
• If missed for 2-4 weeks, the dose is typically reduced by 25% to 50%.
• If missed for more than 4 weeks, the treatment may need to be restarted from a much lower concentration.

An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current threshold of tolerance, leading to a systemic reaction or anaphylaxis.

• Signs: Hives, itching, swelling of the throat, wheezing, shortness of breath, drop in blood pressure, or abdominal cramping.
• Emergency Measures: Immediate administration of Epinephrine (1:1000) intramuscularly, followed by antihistamines, corticosteroids, and oxygen as needed. Emergency medical services (911) should be summoned for any systemic reaction.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to self-administer these injections or adjust your schedule without medical guidance.

Most patients undergoing testing or treatment with Calochortus Tolmiei Whole will experience local reactions. These are generally considered expected and manageable.

• Local Erythema: Redness at the site of injection or skin test. This usually appears within minutes and may last for several hours.
• Pruritus: Itching at the site, which can be intense but typically subsides within an hour.
• Wheal Formation: A raised, pale bump at the injection site. For immunotherapy, a wheal smaller than the size of a quarter is usually considered a normal local reaction.

• Large Local Reactions (LLRs): Swelling and redness that exceeds 5-10 cm in diameter. These may be delayed, appearing 6 to 24 hours after the injection. While not dangerous, they often necessitate a dose reduction in the next treatment.
• Fatigue: Some patients report feeling unusually tired for several hours following an immunotherapy injection.
• Headache: Mild tension-type headaches have been reported following allergen exposure.

• Generalized Urticaria: Hives appearing on parts of the body distant from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Gastrointestinal Distress: Nausea or abdominal cramping as part of a systemic allergic response.

> Warning: Stop taking Calochortus Tolmiei Whole and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.

• Respiratory Distress: Wheezing, chest tightness, or difficulty breathing. This indicates bronchospasm, a serious allergic manifestation.
• Laryngeal Edema: A 'lump in the throat,' hoarseness, or difficulty swallowing, indicating airway swelling.
• Hypotension: Feeling faint, dizzy, or passing out, which may indicate a dangerous drop in blood pressure (anaphylactic shock).
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.
• Tachycardia: A rapid or pounding heartbeat, often accompanied by a sense of impending doom.

There are no known long-term 'toxic' side effects of Calochortus Tolmiei Whole, as it is a biological protein extract. The primary long-term risk is the development of new sensitivities or the rare possibility of 'serum sickness,' though this is extremely uncommon with modern, highly purified extracts. Most patients find that the long-term benefit of reduced allergy symptoms far outweighs the transient discomfort of the injections.

WARNING: RISK OF ANAPHYLAXIS

Calochortus Tolmiei Whole, like all allergenic extracts, can cause severe, life-threatening systemic reactions, including anaphylaxis.

• Injections must be administered in a facility equipped to treat anaphylaxis.
• Patients must be observed for at least 30 minutes post-injection.
• Patients with unstable or severe asthma are at increased risk for fatal reactions.
• Some medications, such as beta-blockers, may interfere with the treatment of anaphylaxis and increase risk.

Report any unusual symptoms or large local reactions to your healthcare provider before your next scheduled dose.

Calochortus Tolmiei Whole is intended only for use by physicians experienced in the diagnosis and treatment of allergic diseases. The potency of non-standardized extracts can vary between manufacturers and even between different lots from the same manufacturer. Therefore, extreme caution must be exercised when switching a patient from one vial to another.

No FDA black box warnings are specific to Calochortus tolmiei alone, but the class-wide black box warning for allergenic extracts applies. This warning emphasizes that these products can cause severe systemic reactions, including death. It mandates that healthcare providers be prepared to manage anaphylaxis and that patients be screened for risk factors such as uncontrolled asthma or the use of beta-blockers.

Allergic Reactions / Anaphylaxis Risk

The risk of a systemic reaction is always present. Factors that increase this risk include:

• High level of sensitivity (determined by skin test reactivity).
• Rapid dose escalation.
• Use of a new vial/lot.
• Exercise within 2 hours after an injection (increases systemic absorption).
• High pollen counts in the environment during the time of injection.

Asthma Status

Patients with asthma must be stable before receiving an injection. If a patient is experiencing an asthma flare or has a reduced peak flow reading, the injection should be postponed. Uncontrolled asthma is the single greatest risk factor for a fatal reaction to immunotherapy.

Cardiovascular Risks

Patients with significant cardiovascular disease are at higher risk if anaphylaxis occurs, as their hearts may not tolerate the stress of the reaction or the effects of the epinephrine required to treat it.

No routine laboratory tests (like CBC or LFTs) are required for patients on Calochortus Tolmiei Whole. However, clinical monitoring is essential:

• Pre-injection Screening: Patients should be asked about their current health, any new medications, and the size of the reaction from their previous dose.
• Peak Flow: For asthmatic patients, a peak flow measurement may be taken before each injection to ensure they are at their baseline.
• Post-injection Observation: Vital signs and the injection site must be monitored for 30 minutes.

While Calochortus Tolmiei Whole does not cause sedation, a systemic reaction can cause dizziness or loss of consciousness. Patients should ensure they feel completely well before driving away from the clinic after their 30-minute observation period.

Alcohol consumption should be avoided on the day of an injection. Alcohol causes vasodilation, which may increase the rate of absorption of the allergen and potentially increase the risk or severity of a systemic reaction.

Immunotherapy can be discontinued if the patient experiences a severe systemic reaction that cannot be managed by dose adjustment. For most patients, treatment is discontinued after 3 to 5 years of successful maintenance, as studies show that the benefits often persist for years after stopping.

> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before starting Calochortus Tolmiei Whole.

• Beta-Blockers (including eye drops): These medications (e.g., propranolol, metoprolol, timolol) are generally contraindicated in patients receiving immunotherapy. Beta-blockers can increase the severity of anaphylaxis and, more importantly, can make the patient's heart and lungs unresponsive to the life-saving effects of epinephrine.

• ACE Inhibitors: Some evidence suggests that patients taking ACE inhibitors (e.g., lisinopril) may be at a higher risk for more severe systemic reactions to allergenic extracts.
• MAO Inhibitors (MAOIs): Drugs like phenelzine or tranylcypromine can potentiate the effects of epinephrine, leading to a risk of hypertensive crisis if epinephrine must be used to treat an allergic reaction.
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs (e.g., amitriptyline) can interfere with the metabolism of epinephrine, complicating the management of anaphylaxis.

• Other Immunotherapy: If a patient is receiving multiple types of immunotherapy (e.g., for venom and pollen), the injections should be spaced out or given in different limbs to avoid cumulative local or systemic reactions.

There are no direct food interactions with Calochortus Tolmiei Whole. However, patients with a 'pollen-food allergy syndrome' (Oral Allergy Syndrome) may find that eating certain related raw fruits or vegetables (though less common with lilies) might prime their immune system, making them more reactive on the day of their injection.

There are no well-documented interactions with herbal supplements. However, supplements that have immune-modulating effects (such as Echinacea or high-dose Astragalus) should be discussed with an allergist, as they could theoretically interfere with the goal of inducing immunological tolerance.

• Skin Testing Suppression: The most significant interaction is with medications that suppress the 'wheal-and-flare' response, leading to false-negative skin test results. These must be stopped before testing:
• First-generation Antihistamines (e.g., diphenhydramine): Stop 3-5 days before.
• Second-generation Antihistamines (e.g., loratadine, cetirizine): Stop 7-10 days before.
• H2 Blockers (e.g., famotidine): Stop 24-48 hours before.
• Topical Corticosteroids: Avoid applying to the test site for at least 2-3 weeks.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any heart or blood pressure medications.

Calochortus Tolmiei Whole must NEVER be used in the following circumstances:

• Severe, Uncontrolled Asthma: Patients with a FEV1 consistently below 70% of predicted or those experiencing an acute exacerbation are at an unacceptably high risk of a fatal reaction.
• Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months, or any unstable angina, as these patients cannot tolerate the physiological stress of anaphylaxis or epinephrine.
• History of Severe Reaction to this Specific Extract: If a patient has previously experienced life-threatening anaphylaxis despite dose adjustments, the risks outweigh the benefits.
• Inability to Communicate: Patients who cannot report early symptoms of a reaction (e.g., very young children or those with severe cognitive impairment) may not be suitable candidates for immunotherapy.

Conditions requiring careful risk-benefit analysis include:

• Autoimmune Diseases: There is a theoretical risk that immunotherapy could exacerbate underlying autoimmune conditions, although data is limited.
• Malignancy: Patients with active cancer may have altered immune systems that respond unpredictably to immunotherapy.
• Pregnancy (Starting Treatment): Immunotherapy should generally not be started during pregnancy, though maintenance doses can often be continued.
• Beta-blocker Therapy: If the medication cannot be switched to an alternative class, immunotherapy is usually avoided.

Patients allergic to Calochortus Tolmiei Whole may show cross-sensitivity to other members of the Liliaceae (Lily) family, which includes various ornamental lilies, tulips, and even some edible plants like onions and garlic. This cross-reactivity is due to shared protein structures (homologous proteins) across the family. Healthcare providers should be aware that testing for one member of this family may result in positive reactions for others.

> Important: Your healthcare provider will evaluate your complete medical history, including heart and lung health, before prescribing Calochortus Tolmiei Whole.

FDA Pregnancy Category C.

Calochortus Tolmiei Whole has not been studied in pregnant women. The primary risk during pregnancy is not the extract itself, but the risk of maternal anaphylaxis. Anaphylaxis can lead to maternal hypotension and uterine contraction, resulting in fetal hypoxia (lack of oxygen) and potential fetal death or injury.

• Starting Treatment: It is standard clinical practice to NOT initiate immunotherapy during pregnancy.
• Continuing Treatment: If a patient is already on a stable maintenance dose and becomes pregnant, the treatment may be continued, as the risk of a reaction is lower during the maintenance phase. However, the dose is typically not increased during pregnancy.

It is not known whether the components of Calochortus Tolmiei Whole are excreted in human milk. However, because the active components are large proteins that are likely degraded in the infant's digestive tract, the risk to the nursing infant is considered negligible. The decision to continue immunotherapy while breastfeeding should be made based on the mother's clinical need.

While safe and effective for children, the use of Calochortus Tolmiei Whole in the pediatric population requires careful consideration. Children under age 5 may have difficulty describing the early symptoms of a systemic reaction (such as an itchy throat or a sense of doom). Most allergists prefer to wait until a child is at least 5 to 6 years old before starting immunotherapy. Dosing is not weight-based; children receive the same concentrations as adults, as the goal is to modulate the immune system's threshold.

Elderly patients (over 65) may be at higher risk for complications from immunotherapy due to the higher prevalence of cardiovascular disease and the use of concomitant medications like beta-blockers or ACE inhibitors. A thorough evaluation of cardiac status is required before starting treatment in this age group. Pharmacokinetic changes associated with aging (reduced renal or hepatic clearance) do not significantly affect the use of this biological extract.

No specific studies have been conducted in patients with renal impairment. However, given the nature of the product (trace amounts of protein), no dose adjustments are anticipated. The clinician should focus on the patient's overall stability and ability to tolerate emergency medications.

No adjustments are required for patients with hepatic impairment. The metabolism of allergenic proteins occurs via general proteolytic pathways and is not dependent on specific hepatic enzyme systems like the Cytochrome P450 system.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have underlying heart or lung conditions.

Calochortus Tolmiei Whole acts as an exogenous antigen. In the diagnostic setting, it cross-links IgE antibodies on the surface of mast cells, leading to the release of histamine and other mediators (Type I Hypersensitivity). In the therapeutic setting, chronic, low-dose exposure via subcutaneous injection induces a shift in the immune response. This includes the induction of T-regulatory (Treg) cells, which secrete IL-10, and a shift in B-cell production from IgE to IgG4. This 'blocking' IgG4 antibody prevents the allergen from reaching the IgE on mast cells, thereby inhibiting the allergic cascade.

The dose-response relationship for allergenic extracts is characterized by a threshold effect. A patient will not react until a certain concentration of allergen is reached. As the patient progresses through immunotherapy, this threshold increases, allowing them to tolerate higher environmental exposures. The duration of effect for a single injection is short, but the cumulative effect on the immune system can last for several years after a full 3-5 year course of treatment.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Local) |

| Protein Binding | N/A (Interacts with IgE/IgG) |

| Half-life | Hours (proteins); Years (immune effect) |

| Tmax | 15-30 minutes (local reaction) |

| Metabolism | Proteolytic degradation |

| Excretion | Renal (metabolites) |

Calochortus Tolmiei Whole extract is a sterile liquid containing the water-soluble proteins, carbohydrates, and lipids extracted from the whole plant of Calochortus tolmiei.

• Molecular Formula: Complex mixture (not a single formula).
• Solubility: Soluble in aqueous solutions; often stabilized in 50% glycerin.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for the primary allergenic proteins.

Calochortus Tolmiei Whole is classified as a Non-Standardized Plant Allergenic Extract. It belongs to the broader therapeutic class of Allergen Immunotherapy agents. It is related to other Liliaceae extracts and other non-standardized weed or flower extracts used in allergy medicine.